Reneo shareholders elect three Class III directors, ratify auditor at 2023 annual meeting

OnKure Therapeutics, Inc.

Elected all three Class III director nominees: Mathers 15.75M for, Muralidhar 15.42M for, Seltzer 15.94M for; 3.76M broker non-votes each.
Ratified Ernst & Young as independent auditor for FY2023 with 20.32M votes for, 12.6K against, 100 abstain.
Record date April 10, 2023; 25,107,430 shares outstanding entitled to vote.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OnKure Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-06 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-06

Exact text from the filing

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: For Against Abstain Broker Non-Votes 20,316,020 12,633 100 -

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OnKure Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-06 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-06

Exact text from the filing

Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: For Abstain Broker Non-Votes Edward T. Mathers 15,749,259 815,951 3,763,543 Bali Muralidhar, M.D., Ph.D. 15,423,901 1,141,309 3,763,543 Stacey D. Seltzer 15,937,901 627,309 3,763,543

View on SEC.gov

160 shareholder votes filed in the last 30 days. Browse all shareholder votes →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-026807

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.